Lynn Kirkpatrick

Lynn Kirkpatrick is an accomplished pharmaceutical executive with extensive experience in drug development and academic leadership. Currently serving as CEO of Ensysce Biosciences since January 2009, Lynn focuses on transformative chemistry aimed at enhancing the safety and efficacy of prescription drugs, particularly in reducing the risks of opioid abuse and overdose. Simultaneously, Lynn leads PHusis Therapeutics in developing novel therapies for diseases with limited treatment options. Prior leadership roles include Chief Scientific Officer at Oncothyreon, Inc. and CEO at ProlX Pharmaceuticals Corporation. Lynn also held a professorship at the University of Regina for over 15 years. Lynn's academic background includes a Postdoctoral Fellowship in Pharmacology from Yale School of Medicine and a PhD in Medicinal and Biomedicinal Chemistry from the University of Saskatchewan.